Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Ross Stores increased its full-year comparable sales and earnings per share guidance after reporting a strong first quarter marked by a 17% jump in comparable-store sales and a profit of $2.02 per share. Management cited broad gains in customer counts across income levels, ethnicities and ages, keeping momentum for the off-price channel even amid l…
Equitable Holdings director Francis Hondal has increased his ownership of the company by acquiring shares through dividend reinvestment and receiving a vested stock grant. These transactions occurred while the company reported strong first-quarter earnings that surpassed market expectations, providing an overview of internal confidence amidst recen…
Rolls-Royce (RYCEY) looks like a constructive long setup: core aerospace and aftermarket profitability remains solid, the company sits squarely in the early winners' circle for small modular reactors (SMRs) after fresh UK funding, and the stock has pulled back on sentiment rather than fundamentals. This trade targets a recovery toward the 52-week h…
Jupiter Neurosciences announced the closing of a $2 million registered direct offering, issuing over 7 million shares to strengthen its cash position. The capital raise extends the company's cash runway to fund its Phase 2a clinical trial for Parkinson’s disease and supports debt reduction efforts to improve shareholder equity. Additionally, funds …
Akari Therapeutics saw its stock jump 50% in after-hours trading after releasing preclinical results that show its lead TROP2-targeting ADC, AKTX-101, produces synergistic cell killing when combined with the KRAS inhibitor adagrasib in pancreatic cancer cell lines carrying KRAS G12D and G12C mutations. The findings, presented in an abstract for the…
James E. Apostolides, Chief Infrastructure & Performance Officer at Baker Hughes Co (BKR), recently reported selling shares of the company’s Class A Common Stock through a pre-arranged trading plan. This transaction occurred as BKR stock maintains proximity to its 52-week high and follows announcements of strong first-quarter fiscal 2026 performanc…
Black Diamond Therapeutics announced positive Phase 2 clinical trial results of silevertinib, an oral brain-penetrant EGFR inhibitor, in treatment-naïve patients with non-small cell lung cancer (NSCLC) harboring non-classical EGFR mutations. The study demonstrated a median progression-free survival of 15.2 months, a 60% objective response rate, and…
MPLX pairs a near-8% distribution with stable, fee-based cash flows and multiple growth projects coming online. At $55.65 the unit is trading on reasonable multiples (P/E ~12, EV/EBITDA 14.2) while returning >$5.8B in distributable cash flow and $3.9B in free cash flow. This trade favors a mid-term, income-with-upside approach: enter at $55.65, sto…
Maggie Chu, Senior Vice President and Chief Human Resources Officer at Littelfuse Inc., reported selling a significant amount of company stock in May 2026. This transaction occurred after her prior acquisition of shares through the exercise of options. The report details the specifics of both the sales and purchases, against a backdrop of recent po…
Autolus Therapeutics announced publication and upcoming presentation of clinical data from the FELIX Phase Ib/II trial on their T cell therapy candidate obe-cel at the ASCO 2026 meeting. The data shows a 59% overall response rate and median duration of response of 42.6 months in adult patients with relapsed/refractory B-cell acute lymphoblastic leu…
Director Robert C. Lieber recently sold a substantial block of Tutor Perini Corp (TPC) shares, following an 117% stock increase over the past year. This sale was followed by a small acquisition of shares as compensation for his board retainer fee. In separate company news, TPC reported Q1 2026 earnings that slightly missed analyst expectations, whi…
Equus Total Return, Inc. announced its net asset value (NAV) increased to $1.50 per share as of March 31, 2026, up from $1.19 at the end of 2025. The rise was largely due to a $5 million increase in the value of its holdings in Morgan E&P, Inc., benefiting from higher crude oil prices. Despite a slight decrease in the value of its holdings in Citro…
Eikon Therapeutics, Inc. (Nasdaq: EIKN), a late-stage clinical biopharmaceutical company focused on oncology, announced the availability of six abstracts for presentation at the 2026 American Society of Clinical Oncology Annual Meeting. The presentations will highlight updated clinical data and progress for Eikon's advanced drug candidates, includi…
North American Construction Group Ltd. reported the outcomes of its Annual and Special Meeting held on May 20, 2026. Shareholders elected seven directors, approved KPMG LLP as independent auditors, ratified an Advance Notice Bylaw, and passed a non-binding advisory vote on executive compensation. The company operates in heavy civil construction and…
Michael Benjamin Tannenbaum, the CEO and Director of Figure Technology Solutions, Inc. (NASDAQ:FIGR), recently executed significant stock transactions totaling approximately $627,370 in sales. These sales occurred while the stock was experiencing a notable decline from its 52-week high. Concurrently, the filing details Tannenbaum's acquisition of s…
U.S. equity markets concluded a volatile Thursday with positive gains, buoyed by hopes of an imminent peace agreement between the U.S. and Iran. While market participants closely monitored Nvidia's earnings, significant attention was directed toward the potential upcoming initial public offerings (IPOs) from tech giants SpaceX and OpenAI. These pro…
Udaychandra Devasper, the Chief Financial Officer (CFO) of Stardust Power Inc. (NASDAQ:SDST), executed a sale of company common stock totaling $72,625 on May 19, 2026. This transaction, involving 35,776 shares sold at an average price of $2.03 per share, was reported via SEC Form 4 and reportedly covered tax withholding obligations related to the s…
Stardust Power's Chief Operating Officer, Chris Edward Celano, sold a portion of his company stock. This activity occurred against a backdrop of Q1 2026 financial results that showed a net loss increase but also highlighted improvements in operational cost management and strategic progress in lithium refining. The stock continues to trade at levels…
Moleculin Biotech's pooled cardiac safety data for its lead drug candidate Annamycin has been accepted for poster presentation at the 2026 ASCO Annual Meeting. The data shows no significant cardiotoxicity even at high cumulative doses, supporting the differentiated safety profile of Annamycin in treating acute myeloid leukemia and soft tissue sarco…
Regeneron announced positive Phase 1/2 LINKER-AL2 trial results for Lynozyfic (linvoseltamab) monotherapy in patients with relapsed or refractory systemic amyloid light chain (AL) amyloidosis. Lynozyfic demonstrated deep and rapid hematologic complete responses in all treated patients at the highest dose, with notable improvements in organ function…
Morgan Lekstrom, Interim Executive Chairman of Streamex Corp., recently acquired a significant block of the company's common stock. This insider buying occurs while the stock trades near its 52-week lows, following recent quarterly earnings that missed analyst forecasts. The transactions highlight internal interest amid the firm's ongoing effort to…
Syndax Pharmaceuticals announced that four abstracts involving its FDA-approved menin inhibitor Revuforj (revumenib) have been accepted for presentation at the ASCO 2026 Annual Meeting. Key highlights include an oral presentation showing favorable outcomes in acute leukemia patients receiving revumenib post-hematopoietic stem cell transplantation a…
Akari Therapeutics announced positive preclinical data demonstrating that their lead antibody drug conjugate (ADC), AKTX-101, synergizes with KRAS inhibitors (including adagrasib) to enhance cytotoxic activity against KRAS-mutated pancreatic cancer models. Unlike traditional ADCs, AKTX-101 uses a novel RNA spliceosome modulating payload (PH1) that …
AerSale Corporation announced that CFO Martin Garmendia will present at the upcoming 2026 Jefferies Aftermarket MRO Virtual Summit and hold investor meetings. The company provides aviation aftermarket services including aircraft and engine sales, leasing, and MRO services. The webcast presentation will be available live and replayed on the company’…
Navient Corporation declared a second quarter 2026 dividend of $0.16 per common share, payable on June 19, 2026, to shareholders of record as of June 5, 2026. The company continues to focus on responsible lending, refinancing options, and financial services through its Earnest business unit.
